Effects of Exemestane, Anastrozole and Tamoxifen on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Early Breast Cancer Patients: Results of N-SAS BC 04, the TEAM Japan Substudy-Reference-Cited by-同舟云学术

Effects of Exemestane, Anastrozole and Tamoxifen on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Early Breast Cancer Patients: Results of N-SAS BC 04, the TEAM Japan Substudy

Published:2010 Issue:5-6 Volume:79 Page:376-381
ISSN:1423-0232
Container-title:Oncology
language:en
Short-container-title:Oncology

Author:

Aihara T.,Suemasu K.,Takei H.,Hozumi Y.,Takehara M.,Saito T.,Ohsumi S.,Masuda N.,Ohashi Y.

Publisher

S. Karger AG

Subject

Cancer Research,Oncology,General Medicine

Reference24 articles.

1. Emerging Role of Aromatase Inhibitors in the Adjuvant Setting

2. A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer

3. ATAC trial update

4. A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer

5. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS);Frontiers in Pharmacology;2023-11-01

2. Management of cancer treatment-induced bone loss (CTIBL) in patients with breast cancer or prostate cancer;Journal of Bone and Mineral Metabolism;2023-04-10

3. Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside;ENDOCRINOLOGY;2021

4. Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside;Endocrinology;2021-09-04

5. Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer;Journal of Bone Oncology;2021-06